article thumbnail

Aggressive Selling: The High-Stakes Game of Push and Profit

Contrarian Sales Techniques

Ethical Considerations: The Fine Line in Sales The Question of Morality in Sales Techniques The ethics of aggressive selling are often debated. Regulatory Scrutiny and Consumer Protection Governments and consumer protection agencies have started scrutinizing aggressive selling techniques.

Ethics 40
article thumbnail

The Future of Medical Sales Careers: Trends, Challenges, and Opportunities

Rep-Lite

Sales professionals are also leveraging video conferencing, online presentations, and virtual demonstrations to engage with clients and prospects from afar. Regulatory Changes and Compliance Challenges Navigating the intricacies of healthcare sales involves staying attuned to the ever-evolving regulatory framework that governs the industry.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Traditional Pharma Model Isn’t Working – It’s Time to Evolve!

PharmaKinnex

But what happens when that in-person meeting is no longer a viable option for your prospect? Outside of the internal pressure from the pharmaceutical industry, governments around the world have also begun to crack down on pharma sales/marketing practices long considered commonplace (and highly profitable).

Pharma 52
article thumbnail

Data-Driven Connections: Linking Rare Disease Patients to Clinical Trials, Experts, and Resources

PM360

Rare Disease and Real-world Evidence Governments around the world are implementing guidelines and developing strategies for the role real-world data (RWD) will play in regulatory decision-making. How can we design clinical trials without an understanding of the natural history of disease? In the U.S.,

article thumbnail

Legal challenges put off label use of gender affirming care drugs in jeopardy

Pharmaceutical Technology

Dr. Edmund Horowicz PhD, a lecturer in medical law and ethics at the University of Liverpool, counters discourse from those such as the Norwegian Healthcare Investigation Board UKOM , that characterises puberty blockers as “experimental” and untrustworthy due to their off-label prescription. But the funding is not there, he adds.

Ethics 144